Patents by Inventor Arne Slungaard

Arne Slungaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating inflammation and associated complications
    Publication number: 20040028749
    Abstract: The invention provides methods and materials related to the treatment of inflammation. Such inflammations include, without limitation, those inflammations mediated by eosinophils and/or neutrophils as well as those inflammations associated with peroxidase activity. The invention also provides methods and materials related to the treatment of complications associated with eosinophil-mediated inflammations and/or neutrophil-mediated inflammations. Specifically, the invention involves increasing the amount of pseudohalides in a mammal exhibiting inflammation and/or an associated condition.
    Type: Application
    Filed: May 1, 2003
    Publication date: February 12, 2004
    Inventors: Arne Slungaard, Stanley L. Hazen, Husam M. Abu-Soud
  • Method to enhance thrombomodulin APC generation using cationic proteins
    Patent number: 5674489
    Abstract: A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein; wherein the cationic protein has an isoelectric point of at least about 7.4, and is capable of enhancing the production of activated protein C by a thrombomodulin-thrombin complex by a factor of at least about two. A particularly preferred cationic protein is purified Platelet Factor 4.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: October 7, 1997
    Assignee: Regents of the University of Minnesota
    Inventor: Arne Slungaard
  • Method to enhance thrombomodulin APC generation using cationic proteins
    Patent number: 5585095
    Abstract: A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein; wherein the cationic protein has an isoelectric point of at least about 7.4, and is capable of enhancing the production of activated protein C by a thrombomodulin-thrombin complex by a factor of at least about two. A particularly preferred cationic protein is purified Platelet Factor 4.
    Type: Grant
    Filed: September 14, 1993
    Date of Patent: December 17, 1996
    Assignee: Regents of the University of Minnesota
    Inventor: Arne Slungaard